*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
293T , A431 , H1299 , HeLaS3
1XPBS, 40% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human CYP2A. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
cytochrome P450 family 2 subfamily A member 6 , CPA6 , CYP2A , CYP2A3 , CYPIIA6 , P450C2A , P450PB
Endoplasmic reticulum membrane , Microsome membrane
This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6. [provided by RefSeq]
GTX103360 WB Image
Sample (30 ug of whole cell lysate)
7.5% SDS PAGE
GTX103360 diluted at 1:1000